Wilson Disease Drugs Market Size & Share, by Indication (Hepatic, Neurological, Ophthalmic, Psychiatric); Drug Type (Chelating Agents, Zinc, Tetrathiomolybdate); End-user (Hospitals, Pharmacies, Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 2863
  • Published Date: Mar 16, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2035

Wilson Disease Drugs Market size is estimated to reach USD 900 million by the end of 2035, growing at a CAGR of 4% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of wilson disease drugs was over USD 600 million. The growth of the market can be attributed to the increasing prevalence of Wilson’s disease across the globe, especially in isolated areas. Wilson’s disease is caused by the mutation of the ATP7B gene which is passed on by parents to the child. This disease was observed to occur in 30,000 to 40,0000 people across the globe.

The advent of various organizations and associations in recent years, such as the Wilson Disease Association, an organization that endorses research and clinical investigations for Wilson disease and spreads awareness regarding the latest happening on the symptoms and treatment of Wilson disease, are observed to hike the market growth over the forecast period. Furthermore, the rising introduction of patient assistance programs which provides considerable growth opportunities to the companies for the development of novel therapeutic drugs for the treatment of Wilson disease is also anticipated to significantly propel the growth of the global Wilson disease drugs market during the forecast period. 


Wilson Disease Drugs Market
Get more information on this report: Request Free Sample PDF

Wilson Disease Drugs Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Prevalence of Wilson’s Disease in Young Population – Wilson’s disease generally occurs in the younger population since it is passed on to children by their parents and shows symptoms at an early age. The symptoms of Wilson’s disease include stomach aches, swelling, weariness, and others.  For instance, the most common age at which symptoms of this disease appears is 12 and 13.
  • Escalating Trial on Gene Therapy – gene therapy is highly advantageous in treating Wilson’s disease since it transits the working ATP7B gene into cells that create working transporter proteins. For instance, around 90% of the trial of gene therapy were noticed to be in their early phases while 70% of the were conducted in 2018 in the United States.
  • Increasing Health Spending across the Globe – based on the current expenditure data, global health spending has increased over the past 20 years, doubling in real terms to hit USD 8.5 trillion in 2019 and 9.8% of GDP, up from 8.5 percent in 2000.
  • Growing R&D Expenditure for Clinical Trials – for instance, in 2021, more than 400,000 studies were noticed to be conducted in 200 countries across the globe.

Challenges

  • High Treatment Costs and Lack of Reimbursement Facilities - Despite the presence of improved healthcare infrastructure, there is a high cost associated with these drugs which are used for the treatment of Wilson’s disease. In addition to this, the poor reimbursement policies in developing countries are estimated to hinder the growth of the Wilson’s disease drugs market in the future.
  • Lack of Awareness in Low-Income Countries.
  • Requirement for Higher Initial Investments

Wilson Disease Drugs Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~4%

Base Year Market Size (2022)

~ USD 600 Million

Forecast Year Market Size (2035)

~ USD 900 Million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Wilson Disease Drugs Segmentation

Indication (Hepatic, Neurological, Ophthalmic, Psychiatric)

The global Wilson disease drugs market is segmented and analyzed for demand and supply by indication into hepatic, neurological, ophthalmic, and psychiatric. Out of these types of indications, the neurological segment is estimated to gain the largest market share in the year 2035. Wilson’s disease includes a higher number of neurological indications such as dysarthria (difficulty in speaking), dysphagia (difficulty in swallowing), tremors, poor coordination, spasticity, involuntary movements, muscle rigidity, dystonic posture, and others. Apart from that, the surge in neurological conditions and usage of neurology devices across the globe has also spurred the demand for medical drugs to cure or manage these diseases which are also expected to propel the growth of the segment over the upcoming decades. For instance, based on the statistics released by Pan American Health Organization (PAHO), it was stated that in 2019, nearly 533,172 people died owing to neurological conditions across the globe, out of which, 320,043 were women while 213,129 were men.

Drug Type (Chelating Agents, Zinc, Tetrathiomolybdate)

The global Wilson disease drugs market is also segmented and analyzed for demand and supply by drug type into chelating agents, zinc, tetrathiomolybdate, and others. Amongst these segments, the chelating agents’ segment is expected to garner a significant share in the year 2035. Chelating agents include trientine, penicillamine, and dimercaprol which are helpful in reducing the levels of copper in blood and tissues when administered for a prolonged time period. These agents are further helpful in preventing the gathering of copper and injuries from Wilson disease. Chelating agents are developed to flush toxic metals out of the body. Toxic metals are known to cause immune system dysfunction, nervous systems disorders, cancer, birth defects, skin lesions, vascular damage, and many more. A surge in the nervous system disorder and cancer can be observed across the globe which is expected to hike the segment growth over the forecast period. As of 2020, nearly 10 million people lost their lives worldwide.

Our in-depth analysis of the global market includes the following segments:

          By Indication

  • Hepatic
  • Neurological
  • Ophthalmic
  • Psychiatric

            By Drug Type

  • Chelating Agents
  • Zinc
  • Tetrathiomolybdate
  • Others

            By End-User

  • Hospitals
  • Pharmacies
  • Clinics
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Wilson Disease Drugs Industry - Regional Synopsis

North American Market Forecast

The North American Wilson disease drugs market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed majorly to the presence of leading market players in the region which manufacture and distribute Wilson disease drugs. Moreover, support from the government in the implementation of advanced healthcare technologies, coupled with the rise in the number of patients with hereditary disorders and Wilson’s disease in the region is anticipated to drive the demand for Wilson disease drugs in the region over the forecast period. For instance, it was estimated that in the United States, in every 30,000 individuals, one of them suffers from Wilson’s disease. Additionally, the surge in the geriatric population in this region and growing awareness among people of Wilson’s disease is also anticipated to expand the market size over the forecast period.

APAC Market Statistics

The Asia Pacific Wilson disease drugs market, amongst the market in all the other regions, is projected to hold the second largest share during the forecast period. The growth of the market is backed by a rise in awareness about this rare disorder along with the increase in healthcare expenditure in the region during the forecast period. The developing economies in the region, especially the countries such as China, India, and Japan, are further anticipated to provide significant opportunities for the manufacturing of Wilson disease drugs, and in turn, drive the growth of the market in the region. In Asia Pacific, many key manufacturers are observed to invest a significant amount of money in R&D activities to find new drugs. Hence, all these factors are anticipated to influence the market growth positively over the forecast period.

Research Nester
Wilson Disease Drugs Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Wilson Disease Drugs Landscape

top-features-companies
    • Merck & Co., Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bausch Health Companies Inc.
    • Alexion Pharmaceuticals, Inc.
    • Nobelpharma Co., Ltd.
    • Kodmon Holdings, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Tsumura & Co.
    • VHB Medi Sciences Limited
    • Pfizer Inc.
    • Lupin Limited
    • Vivet Therapeutics
    • NAVINTA LLC

In the News

  • Alexion Pharmaceuticals, Inc. made an announcement regarding the acquisition of LogicBio Therapeutic, Inc. The acquisition took place to accelerate the growth of Alexion Pharmaceuticals in developing genomic medicines using the unique technology of LogicBio.

  • Kadmon Holdings, Inc. announced that its generic Trientine Hydrochloride Capsules USP, 250 mg, which is a chelating agent used for the treatment of Wilson’s disease in patients who are intolerant of penicillamine, has been approved by the U.S. Food and Drug Administration (FDA).

Author Credits:  Radhika Pawar


  • Report ID: 2863
  • Published Date: Mar 16, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing prevalence of Wilson’s disease in the young population and increasing health spending across the globe are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 4% over the forecast period, i.e., 2023-2035.

Lack of awareness in low-income countries and requirement for higher initial investments are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Nobelpharma Co., Ltd., Kodmon Holdings, Inc., Teva Pharmaceutical Industries Ltd., Tsumura & Co., VHB Medi Sciences Limited, Pfizer Inc., Lupin Limited, Vivet Therapeutics, NAVINTA LLC, and others.

The company profiles are selected based on the revenues generated from segments, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by indication, drug type, end-user, and by region.

The neurological segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Wilson Disease Drugs Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying